Funded Biotechnology Startups in Singapore
Disclosed funding sizes in this Singapore biotechnology cut are highly uneven.
Disclosed funding sizes in this Singapore biotechnology cut are highly uneven. The largest disclosed round is RVAC Medicines at $140M (2022-04-26), which sits far above the next-largest disclosed amounts in the $45M–$45M-plus range (Nuevocor at $45M on 2025-05-06, Mirxes at $40M on 2025-01-13, and Apeiron Bioenergy at $37M on 2023-06-23). At the low end, disclosed rounds include BioDefense at $100K (2024-05-14) and Touché at $100K (2022-03-14), illustrating a floor of disclosed amounts versus a wide high tail.
The list clusters temporally around recent activity: most recent entries run from 2026-06-12 (YouLabs, $3M) back to the oldest shown date of 2020-12-17 (TurtleTree Labs, $6M), with multiple dense checkpoints in 2025 (e.g., VolitionRx $5M on 2026-06-07 is close to a 2025 cluster led by Nuevocor and Mirxes). Geographically, every row is Singapore with the same “Central Region” label, and the dataset leans heavily toward unknown or undisclosed deal terms: 6 entries are marked “Series Unknown” and 9 are “undisclosed,” including ImmunoScape (undisclosed, 2026-03-04) and 2Strands Biosciences (undisclosed, 2026-03-01).
Most recent rounds
30 of 311 more funded startups
This page shows the 30 most recent rounds (back to Dec 2020). The full 31-company history for this listing is available on a paid plan.
Unlock all 31 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
What stands out on round size—does one company dominate disclosed totals in this Singapore biotechnology slice?
Yes. RVAC Medicines raised $140M on 2022-04-26, dwarfing the next-largest disclosed amounts such as Nuevocor’s $45M (2025-05-06), Mirxes’ $40M (2025-01-13), and Apeiron Bioenergy’s $37M (2023-06-23). On the floor, BioDefense and Touché both show $100K disclosed rounds (2024-05-14 and 2022-03-14, respectively).
Are deal terms concentrated in “Series Unknown” or “undisclosed,” making stage comparisons harder?
They are. “Series Unknown” appears in 6 rows (e.g., VolitionRx on 2026-06-07 for $5M, and Aevice Health on 2025-01-15 for undisclosed amount), while “undisclosed” appears in 9 rows (e.g., ImmunoScape on 2026-03-04 and 2Strands Biosciences on 2026-03-01). That reduces how often stages can be compared using explicit labels.
Which timeframe clusters are most visible across the 30 most recent entries shown?
Rounds span 2020-12-17 (TurtleTree Labs, $6M) through 2026-06-12 (YouLabs, $3M), with repeated momentum in 2025: Nuevocor closed $45M on 2025-05-06 and Mirxes closed $40M on 2025-01-13, alongside other 2025 entries. Recent months are also active, including YouLabs (2026-06-12) and VolitionRx (2026-06-07).
Is there an obvious stage mix pattern where early rounds show up more often than later ones?
Broadly, early-stage labels recur, but later-stage funding is represented by large disclosed rounds. For example, multiple “Seed” rounds show $3M–$6M levels (YouLabs is Seed at $3M on 2026-06-12; Auristone $4M on 2024-04-02; DotBio $6M on 2023-08-07), while “Series B/C” includes outsized figures like RVAC Medicines’ $140M (Series B, 2022-04-26) and SCG Cell Therapy’s $8M (Series C, 2023-04-05).
Are there outliers that could warrant separate diligence compared with the rest of the disclosed range?
Two ends of the distribution are especially notable. On the high end, RVAC Medicines’ $140M (2022-04-26) is the clear outlier above the rest of the disclosed amounts; on the low end, BioDefense and Touché both show $100K disclosed rounds (2024-05-14 and 2022-03-14). Together, they frame an unusually wide disclosed range within the same Singapore geography label.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.